XML 66 R45.htm IDEA: XBRL DOCUMENT
v3.22.0.1

Product Revenue Reserves and Allowances - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Dec. 17, 2020 | Mar. 31, 2013 | Aug. 31, 2020 | Feb. 29, 2020 | Jan. 31, 2020 | Aug. 31, 2019 | Nov. 30, 2018 | Dec. 31, 2021 | Dec. 31, 2020
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | $ 36,939,000 | $ 34,437,000
Icon Bioscience Inc [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Sales-based royalty expense |  |  |  |  |  |  |  | 0 | $ 1,300,000
Percentage of accelerated milestone payment received |  |  |  |  |  |  |  |  | 20.00%
Amended Alimera Science Inc Agreement [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 54,000 | $ 1,700,000
OncoSil Medical UK Limited [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 0 |
Deferred revenue |  |  |  |  |  |  |  | $ 100,000 | 100,000
Receipt of upfront license fee |  | $ 100,000 |  |  |  |  |  |  |
Royalty percentage earned from sales of product |  |  |  |  |  |  |  | 8.00% |
Percentage of non-royalty consideration received from sublicense |  |  |  |  |  |  |  | 20.00% |
License agreement commencement date |  |  |  |  |  |  |  | 2012-12 |
Ocumension Therapeutics [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | $ 0 | $ 0
Receipt of upfront license fee |  |  | $ 9,500,000 | $ 2,000,000.0 |  |  | $ 1,750,000 |  |
Potential future payments based on achievement of development and regulatory milestones |  |  | 6,000,000.0 |  | $ 6,000,000.0 |  |  | 7,250,000 |
Potential future payments based on achievement of commercial-based milestones |  |  | 6,000,000.0 |  | $ 6,000,000.0 |  |  | 3,000,000.0 |
Development milestone payment received |  |  |  |  |  | $ 1,000,000.0 |  |  |
Potential future payments based on achievement of combined remaining development and sales milestone |  |  | 11,750,000 |  |  |  |  |  |
Potential future payments based on achievement of remaining development and regulatory milestones |  |  | 6,250,000 |  |  |  |  |  |
Potential future payments based on achievement of remaining commercial-based milestones |  |  | 3,000,000.0 |  |  |  |  |  |
Ocumension Therapeutics [Member] | Share Offering [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Issuance of stock, net of issue costs, shares |  |  |  |  |  |  |  |  | 3,010,722
Ocumension Therapeutics [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Product supply milestones and development milestones |  |  |  |  |  |  |  | 7,250,000 |
Upon achievement of milestones |  |  | $ 21,250,000 |  |  |  |  |  |
Royalty Income [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 871,000 | $ 1,664,000
Royalty Income [Member] | Amended Alimera Science Inc Agreement [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 0 | 1,700,000
RPA [Member] | SWK [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 872,000 | 0
Upfront cash payment | $ 16,500,000 |  |  |  |  |  |  |  |
Royalty payments |  |  |  |  |  |  |  | 2,800,000 |
Royalty Sale Agreement [Member] | SWK [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Deferred revenue | $ 16,500,000 |  |  |  |  |  |  |  |
Deferred revenue, current |  |  |  |  |  |  |  | 1,100,000 | 885,000
Deferred revenue, non-current |  |  |  |  |  |  |  | 14,600,000 | 15,600,000
Collaborative Research and Development [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 60,000 | 255,000
Deferred revenue |  |  |  |  |  |  |  | 0 | 60,000
Collaborative Research and Development [Member] | OncoSil Medical UK Limited [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 100,000 |
License and Collaboration Agreement [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 756,000 | 11,942,000
License and Collaboration Agreement [Member] | Ocumension Therapeutics [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 543,000 | 11,500,000
Product [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 35,312,000 | 20,831,000
Product [Member] | Ocumension Therapeutics [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | 308,000 | 213,000
Technical Assistance [Member] | Ocumension Therapeutics [Member] |  |  |  |  |  |  |  |  |
Disclosure of Product Revenue Reserves and Allowances [Line Items] |  |  |  |  |  |  |  |  |
Revenue |  |  |  |  |  |  |  | $ 499,000 | $ 0

X
- Definition Development milestone payment received. + References No definition available. + Details
Name: | eypt_DevelopmentMilestonePaymentReceived
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition License Agreement Start Year Month + References No definition available. + Details
Name: | eypt_LicenseAgreementStartYearMonth
Namespace Prefix: | eypt_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non royalty consideration percentage. + References No definition available. + Details
Name: | eypt_NonRoyaltyConsiderationPercentage
Namespace Prefix: | eypt_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of accelerated milestone payment received. + References No definition available. + Details
Name: | eypt_PercentageOfAcceleratedMilestonePaymentReceived
Namespace Prefix: | eypt_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential future payments to be received upon the achievement of prescribed combined remaining development and sales milestone. + References No definition available. + Details
Name: | eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCombinedRemainingDevelopmentAndSalesMilestone
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential future payments to be received upon the achievement of prescribed commercial sales-based milestone. + References No definition available. + Details
Name: | eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedCommercialSalesBasedMilestone
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential future payments to be received upon the achievement of prescribed development and regulatory milestone. + References No definition available. + Details
Name: | eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedDevelopmentAndRegulatoryMilestone
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential future payments to be received upon the achievement of prescribed remaining commercial sales-based milestone. + References No definition available. + Details
Name: | eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingCommercialSalesBasedMilestone
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Potential future payments to be received upon the achievement of prescribed remaining development and regulatory milestone. + References No definition available. + Details
Name: | eypt_PotentialFuturePaymentsToBeReceivedUponAchievementOfPrescribedRemainingDevelopmentAndRegulatoryMilestone
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Product supply milestones and development milestones. + References No definition available. + Details
Name: | eypt_ProductSupplyMilestonesAndDevelopmentMilestones
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Royalty percentage earned from sales of product. + References No definition available. + Details
Name: | eypt_RoyaltyPercentageEarnedFromProductSales
Namespace Prefix: | eypt_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Sales based royalty expense. + References No definition available. + Details
Name: | eypt_SalesBasedRoyaltyExpense
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upfront cash payment. + References No definition available. + Details
Name: | eypt_UpfrontCashPayment
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront cash payment received under license agreement. + References No definition available. + Details
Name: | eypt_UpfrontLicenseFeeReceived
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Upon achievement of milestones. + References No definition available. + Details
Name: | eypt_UponAchievementOfMilestones
Namespace Prefix: | eypt_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 + Details
Name: | us-gaap_ContractWithCustomerLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 8 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045 + Details
Name: | us-gaap_ContractWithCustomerLiabilityNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (g) -URI http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of new stock issued during the period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -URI http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682 + Details
Name: | us-gaap_StockIssuedDuringPeriodSharesNewIssues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=eypt_IconBioscienceIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=eypt_AmendedAlimeraScienceIncAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=eypt_OncoSilMedicalUKLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=eypt_OcumensionTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=eypt_UnderwrittenPublicOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eypt_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=eypt_SWKFundingLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eypt_RoyaltySaleAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eypt_CollaborativeResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=eypt_LicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_TechnologyServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |